Furthermore, p53, EGFR and MDM2 are also predictive markers in breast cancer (38), lung cancer (39), blastomatoid pulmonary carcinosarcoma (40), Wilms’ tumor (41), anaplastic thyroid carcinoma (42), bladder cancer (43) and prostate cancer (44). This evidence concerns the gene MDM2 and thyroid gland undifferentiated (anaplastic) carcinoma.